NCT03342300 2020-05-19
PDVPSTS
Peking University People's Hospital
Phase 2/3 Withdrawn
Clinical Trials
9 trialsNCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02557854 2019-03-19
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT01490047 2015-06-16
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Ludwig Institute for Cancer Research
Phase 1 Withdrawn
NCT01281943 2013-07-04
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT00434031 2012-07-30
CETRA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT01333423 2012-06-26
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01492881 2012-05-11
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn